Amgen Hiding Biosimilar Info, Genentech Suit Says

Law360, New York (February 16, 2017, 8:32 PM EST) -- Amgen is hypocritically withholding information about its proposed biosimilar of cancer drug Avastin and thereby undercutting potential patent litigation, Genentech charged in a complaint filed Wednesday in Delaware federal court.

Genentech Inc.’s complaint accuses Amgen Inc. of short-circuiting a section of the Biologics Price Competition and Innovation Act known as the “patent dance.” The dance directs biosimilar makers to disclose approval applications and “other information” about manufacturing, but Amgen has only divulged its application, according to Genentech.

That amounts to “ignoring the express statutory language” of...
To view the full article, register now.




Case Information

Case Title

Genentech, Inc. v. Amgen Inc.

Case Number




Nature of Suit

Other Statutory Actions


Gregory M. Sleet

Date Filed

February 15, 2017

Law Firms


Government Agencies

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.